241 related articles for article (PubMed ID: 32859199)
1. Particle-based, Pfs230 and Pfs25 immunization is effective, but not improved by duplexing at fixed total antigen dose.
Huang WC; Deng B; Mabrouk MT; Seffouh A; Ortega J; Long C; Miura K; Wu Y; Lovell JF
Malar J; 2020 Aug; 19(1):309. PubMed ID: 32859199
[TBL] [Abstract][Full Text] [Related]
2. Antibody response of a particle-inducing, liposome vaccine adjuvant admixed with a Pfs230 fragment.
Huang WC; Deng B; Seffouh A; Ortega J; Long CA; Suresh RV; He X; Miura K; Lee SM; Wu Y; Lovell JF
NPJ Vaccines; 2020; 5(1):23. PubMed ID: 32218995
[TBL] [Abstract][Full Text] [Related]
3. Lyophilized, antigen-bound liposomes with reduced MPLA and enhanced thermostability.
Mabrouk MT; Huang WC; Deng B; Li-Purcell N; Seffouh A; Ortega J; Ekin Atilla-Gokcumen G; Long CA; Miura K; Lovell JF
Int J Pharm; 2020 Nov; 589():119843. PubMed ID: 32890653
[TBL] [Abstract][Full Text] [Related]
4. A malaria vaccine adjuvant based on recombinant antigen binding to liposomes.
Huang WC; Deng B; Lin C; Carter KA; Geng J; Razi A; He X; Chitgupi U; Federizon J; Sun B; Long CA; Ortega J; Dutta S; King CR; Miura K; Lee SM; Lovell JF
Nat Nanotechnol; 2018 Dec; 13(12):1174-1181. PubMed ID: 30297818
[TBL] [Abstract][Full Text] [Related]
5. ELISA units, IgG subclass ratio and avidity determined functional activity of mouse anti-Pfs230 antibodies judged by a standard membrane-feeding assay with Plasmodium falciparum.
Miura K; Deng B; Wu Y; Zhou L; Pham TP; Diouf A; Wu CK; Lee SM; Plieskatt JL; Morin MJ; Long CA
Vaccine; 2019 Apr; 37(15):2073-2078. PubMed ID: 30850239
[TBL] [Abstract][Full Text] [Related]
6. Functional comparison of Plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay.
Miura K; Takashima E; Deng B; Tullo G; Diouf A; Moretz SE; Nikolaeva D; Diakite M; Fairhurst RM; Fay MP; Long CA; Tsuboi T
Infect Immun; 2013 Dec; 81(12):4377-82. PubMed ID: 24042109
[TBL] [Abstract][Full Text] [Related]
7. Experimental and Computational Observations of Immunogenic Cobalt Porphyrin Lipid Bilayers: Nanodomain-Enhanced Antigen Association.
Federizon J; Feugmo CGT; Huang WC; He X; Miura K; Razi A; Ortega J; Karttunen M; Lovell JF
Pharmaceutics; 2021 Jan; 13(1):. PubMed ID: 33466686
[TBL] [Abstract][Full Text] [Related]
8. Vaccine co-display of CSP and Pfs230 on liposomes targeting two Plasmodium falciparum differentiation stages.
Huang WC; Mabrouk MT; Zhou L; Baba M; Tachibana M; Torii M; Takashima E; Locke E; Plieskatt J; King CR; Coelho CH; Duffy PE; Long C; Tsuboi T; Miura K; Wu Y; Ishino T; Lovell JF
Commun Biol; 2022 Aug; 5(1):773. PubMed ID: 35915227
[TBL] [Abstract][Full Text] [Related]
9. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
Arakawa T; Komesu A; Otsuki H; Sattabongkot J; Udomsangpetch R; Matsumoto Y; Tsuji N; Wu Y; Torii M; Tsuboi T
Infect Immun; 2005 Nov; 73(11):7375-80. PubMed ID: 16239536
[TBL] [Abstract][Full Text] [Related]
10. The Pfs230 N-terminal fragment, Pfs230D1+: expression and characterization of a potential malaria transmission-blocking vaccine candidate.
Lee SM; Wu Y; Hickey JM; Miura K; Whitaker N; Joshi SB; Volkin DB; Richter King C; Plieskatt J
Malar J; 2019 Nov; 18(1):356. PubMed ID: 31703583
[TBL] [Abstract][Full Text] [Related]
11. Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice.
Healy SA; Anderson C; Swihart BJ; Mwakingwe A; Gabriel EE; Decederfelt H; Hobbs CV; Rausch KM; Zhu D; Muratova O; Herrera R; Scaria PV; MacDonald NJ; Lambert LE; Zaidi I; Coelho CH; Renn JP; Wu Y; Narum DL; Duffy PE
J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33561016
[TBL] [Abstract][Full Text] [Related]
12. Comparison of carrier proteins to conjugate malaria transmission blocking vaccine antigens, Pfs25 and Pfs230.
Scaria PV; Chen BB; Rowe CG; Alani N; Muratova OV; Barnafo EK; Lambert LE; Zaidi IU; Lees A; Rausch KM; Narum DL; Duffy PE
Vaccine; 2020 Jul; 38(34):5480-5489. PubMed ID: 32600913
[TBL] [Abstract][Full Text] [Related]
13. Combining Monophosphoryl Lipid A (MPL), CpG Oligodeoxynucleotide (ODN), and QS-21 Adjuvants Induces Strong and Persistent Functional Antibodies and T Cell Responses against Cell-Traversal Protein for Ookinetes and Sporozoites (CelTOS) of Plasmodium falciparum in BALB/c Mice.
Pirahmadi S; Zakeri S; Mehrizi AA; Djadid ND; Raz AA; Sani JJ
Infect Immun; 2019 Jun; 87(6):. PubMed ID: 30936155
[No Abstract] [Full Text] [Related]
14. An Engineered Biomimetic MPER Peptide Vaccine Induces Weakly HIV Neutralizing Antibodies in Mice.
Shao S; Huang WC; Lin C; Hicar MD; LaBranche CC; Montefiori DC; Lovell JF
Ann Biomed Eng; 2020 Jul; 48(7):1991-2001. PubMed ID: 31832930
[TBL] [Abstract][Full Text] [Related]
15. Development and characterization of novel carrier gel core liposomes based transmission blocking malaria vaccine.
Tiwari S; Goyal AK; Mishra N; Khatri K; Vaidya B; Mehta A; Wu Y; Vyas SP
J Control Release; 2009 Dec; 140(2):157-65. PubMed ID: 19686788
[TBL] [Abstract][Full Text] [Related]
16. Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013.
Genito CJ; Beck Z; Phares TW; Kalle F; Limbach KJ; Stefaniak ME; Patterson NB; Bergmann-Leitner ES; Waters NC; Matyas GR; Alving CR; Dutta S
Vaccine; 2017 Jul; 35(31):3865-3874. PubMed ID: 28596090
[TBL] [Abstract][Full Text] [Related]
17. Maintaining immunogenicity of blood stage and sexual stage subunit malaria vaccines when formulated in combination.
Parzych EM; Miura K; Long CA; Burns JM
PLoS One; 2020; 15(4):e0232355. PubMed ID: 32348377
[TBL] [Abstract][Full Text] [Related]
18. Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230.
MacDonald NJ; Nguyen V; Shimp R; Reiter K; Herrera R; Burkhardt M; Muratova O; Kumar K; Aebig J; Rausch K; Lambert L; Dawson N; Sattabongkot J; Ambroggio X; Duffy PE; Wu Y; Narum DL
J Biol Chem; 2016 Sep; 291(38):19913-22. PubMed ID: 27432885
[TBL] [Abstract][Full Text] [Related]
19. Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology.
Li Y; Leneghan DB; Miura K; Nikolaeva D; Brian IJ; Dicks MD; Fyfe AJ; Zakutansky SE; de Cassan S; Long CA; Draper SJ; Hill AV; Hill F; Biswas S
Sci Rep; 2016 Jan; 6():18848. PubMed ID: 26743316
[TBL] [Abstract][Full Text] [Related]
20. Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles.
Kumar R; Ray PC; Datta D; Bansal GP; Angov E; Kumar N
Vaccine; 2015 Sep; 33(39):5064-71. PubMed ID: 26299750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
